Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 301–400 of 1,001
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study
von Lewinski, D., Tripolt, N. J., Sourij, H., Pferschy, P. N., Oulhaj, A., Alber, H. F., Gwechenberger, M., Martinek, M., Seidl, S., Moertl, D., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.01.008 · Cited by 34
Chaudhry, K., & Karalliedde, J. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15765 · Cited by 42
Cherney, D. Z. I., McGuire, D. K., Charbonnel, B., Cosentino, F., Pratley, R., Dagogo-Jack, S., Frederich, R., Maldonado, M., Liu, J., Pong, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051901 · Cited by 33
Self-citationThe role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 37
Sarak, B., Verma, S., Mazer, C. D., Teoh, H., Quan, A., Gilbert, R. E., Goodman, S. G., Bami, K., Coelho‐Filho, O. R., Ahooja, V., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01390-8 · Cited by 38
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14769 · Cited by 42
Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M. W., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40060 · Cited by 38
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
Panico, C., Bonora, B. M., Camera, A., Chilelli, N. C., Prato, G. D., Favacchio, G., Grancini, V., Resi, V., Rondinelli, M., Zarra, E., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01855-y · Cited by 39
Mancinetti, F., Xenos, D., Fano, M. D., Mazzieri, A., Porcellati, F., Boccardi, V., & Mecocci, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102018 · Cited by 37
Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
King, R. W., Canonico, M. E., Bonaca, M. P., & Hess, C. N. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100513 · Cited by 36
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 34
“The HR for death from cardiovascular causes and HR for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level were 0.92 (CI 95.8%, 0.77 to 1.11) and 0.81 (CI 95.8%, 0.63 to 1.04), respectively [33–35].”
BackgroundInfluentialChronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 42
Desai, N. R., Olewińska, E., Famulska, A., Rémuzat, C., François, C., & Folkerts, K. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10385-y · Cited by 39
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 41
Kidney outcomes using a sustained ≥40% decline in eGFR : A meta‐analysis of SGLT2 inhibitor trials
Cherney, D. Z. I., Dagogo-Jack, S. E., McGuire, D. K., Cosentino, F., Pratley, R. E., Shih, W. J., Frederich, R. C., Maldonado, M., Liu, J., Wang, S., et al. (2021) · Clinical Cardiology · doi:10.1002/clc.23665 · Cited by 35
“04).(2) A recent meta-analysis of SGLT2 inhibitor outcome trials reported that SGLT2 inhibitors were associated with reduction in the risk of adverse composite kidney outcomes (HR 0.”
BackgroundSelf-citationRau, M., Thiele, K., Hartmann, N. K., Möllmann, J., Wied, S., Hohl, M., Marx, N., & Lehrke, M. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101175 · Cited by 37
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 35
Evolving Diagnostic and Management Advances in Coronary Heart Disease
Ribeiro, M. D. O. L., Correia, V. M., de Oliveira, L. L. H., Soares, P. R., & Scudeler, T. L. (2023) · Life · doi:10.3390/life13040951 · Cited by 44
Sohn, M., Dietrich, J. W., Nauck, M. A., & Lim, S. K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01877-6 · Cited by 34
Lyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 36
“Considering the cardiovascular benefits of SGLT2i in diabetic patients as established in recently published CVOTs [4–7], guidelines recommend prioritizing the use of SGLT2i in patients with type 2 DM and concurrent cardiovascular disease.”
BackgroundTseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
“S3) [7–13, 16, 22, 23, 26–28, 31–41, 50, 51, 53, 54, 61, 63, 74–176], a total of 22 RCTs were included in the analysis [19–21 , 47– 65 ].”
Staplin, N., Roddick, A., Neuen, B. L., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Docherty, K. F., Fletcher, R. A., Inzucchi, S. E., et al. (2025) · JAMA · doi:10.1001/jama.2025.20835 · Cited by 41
Self-citationHtoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Kim, S. C., Najafzadeh, M., Koeneman, L., FARSANI, S. F. F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.37606 · Cited by 33
Wang, Y., Gao, T., Meng, C., Li, S., Bi, L., Geng, Y., & Zhang, P. (2022) · European journal of medical research · doi:10.1186/s40001-022-00945-z · Cited by 36
“The Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF) [21], The Dapagliflozin Effect on Cardiovascular Events– Thrombolysis in Myocardial Infarction 58 (DECLARE– TIMI 58) [22], Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS-CV) [23], and Sot…”
BackgroundAziri, B., Begić, E., Јаnkovic, S., Mladenović, Z., Stanetić, B., Kovačević-Preradović, T., Iglica, A., & Mujaković, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14355 · Cited by 33
Rastogi, T., Ferreira, J. P., Butler, J., Kraus, B. J., Mattheus, M., Brueckmann, M., Filippatos, G. S., Wanner, C., Pocock, S., Packer, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3136 · Cited by 33
Mahé, G., Aboyans, V., Cosson, E., Mohammedi, K., Sarlon-Bartoli, G., Lanéelle, D., Mirault, T., & Darmon, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02325-9 · Cited by 34
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“In this study, participants were randomized in a 1:1:1 ratio to receive either ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo, and were followed for an average duration of 3.5 years [271].”
InfluentialBozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 33
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30153112 · Cited by 35
“Early studies such as EMPA-REG OUTCOME [5], CANVAS [6], DECLARE-TIMI 58 [7], and VERTIS CV [8] demonstrated significant cardiovascular benefits in patients with type 2 diabetes.”
First-line treatment for type 2 diabetes: is it too early to abandon metformin?
Zaccardi, F., Khunti, K., Marx, N., & Davies, M. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32523-x · Cited by 32
Poonawalla, I. B., Bowe, A., TINDAL, M., MEAH, Y. A., & Schwab, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108800 · Cited by 31
Bexagliflozin for type 2 diabetes: an overview of the data
Azzam, O., Carnagarin, R., Lugo‐Gavidia, L. M., Nolde, J. M., Matthews, V. B., & Schlaich, M. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1959915 · Cited by 31
“short of emulating its same class counterparts for MACE and more specifically cardiovascular deaths, it similarly caused a 30% reduction in HHF, notwithstanding its omission of this outcome measure from the hierarchal testing sequence [56].”
BackgroundA Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
Berg, D. D., Wiviott, S. D., Scirica, B. M., Zelniker, T. A., Goodrich, E. L., Jarolím, P., Mosenzon, O., Cahn, A., Bhatt, D. L., Leiter, L. A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-1170 · Cited by 32
Self-citationLi, N., Zhou, G., Zheng, Y., Lv, D., Zhu, X., Wei, P., Zheng, M., Liu, S., Zhou, E., Sun, W., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261986 · Cited by 33
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Herat, L. Y., Matthews, J. R., Azzam, O., Schlaich, M. P., & Matthews, V. B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01170-z · Cited by 33
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
Klen, J., & Dolžan, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071995 · Cited by 38
“eGFR was reduced after ertugliflozin treatment, but the values returned to baseline and were higher after 104 weeks [67].”
BackgroundBhatia, K., Jain, V., Gupta, K., Bansal, A., Fox, A., Qamar, A., Damman, K., & Vaduganathan, M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2135 · Cited by 30
Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Self-citationMałyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
yanchen, L., Cheng, X., & Dong, Q. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02255-6 · Cited by 31
Jaiswal, V., Mashkoor, Y., Raj, N., Rajak, K., Jaiswal, A., & Fonarow, G. C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.030 · Cited by 34
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 33
Crispino, S. P., Segreti, A., Nafisio, V., Valente, D., Crisci, F., Ferro, A., Cavallari, I., Nusca, A., Ussia, G. P., & Grigioni, F. (2025) · Biomedicines · doi:10.3390/biomedicines13030608 · Cited by 37
“[48].”
Heo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 35
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“However, available studies to date have not demonstrated a consistent increase in the risk of lower limb amputation with er-tugliflozin [105,168].”
Provenzano, M., Pelle, M. C., Zaffina, I., Tassone, B., Pujia, R., Ricchio, M., Serra, R., Sciacqua, A., Michael, A., Andreucci, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.654557 · Cited by 34
“Similarly, no significant benefit was observed in the secondary composite renal outcome (115, 120).”
BackgroundVascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 33
Fu, E. L., Clase, C. M., Janse, R. J., Lindholm, B., Dekker, F. W., Jardine, M., & Carrero, J. J. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.042 · Cited by 30
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
Nephroprotective Properties of Antidiabetic Drugs
Gerdes, C., Muller, N., Wolf, G., & Busch, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103377 · Cited by 31
“6%) with ertugliflozin compared to placebo at 60 months [81,82].”
BackgroundGreene, S. J., Butler, J., & Kosiborod, M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.019 · Cited by 29
Greco, A., Canale, M. L., Quagliariello, V., Oliva, S., Tedeschi, A., Inno, A., Biasio, M. D., Bisceglia, I., Tarantini, L., Maurea, N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104780 · Cited by 31
“Despite limitations related to the study design, which focused on the safety of these drugs and likely resulted in an underestimation of their true efficacy [38], these molecules have delivered exceeding expectations on CV events [36,37,39,40].”
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30
“84–87 Ertugliflozin showed no significant difference in either cardiovascular or renal outcomes.(88) This led to subsequent studies showing that canagliflozin and dapagliflozin reduce renal dysfunction, and others showing that dapagliflozin and empagliflozin improve outcomes in HFrEF.”
ResultWilding, J. P. H., Evans, M., Fernando, K., Górriz, J. L., Cebrián, A., Diggle, J., Hicks, D., James, J., Newland‐Jones, P., Ali, A., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01228-w · Cited by 30
“Low absolute incidence of DKA was reported in the canagliflozin CANVAS and CREDENCE studies, no imbalance was demonstrated for DKA episodes in the VERTIS CV trial (ertugliflozin), three episodes of DKA were reported in the dapagliflozin arms of the DAPA-HF study, two cases of ketoacidosis were reported in the placebo…”
BackgroundCao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 33
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
Jhund, P. S. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.010 · Cited by 33
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius, F. C., Cherney, D. Z. I., Gee, P. O., Harris, R. C., Kliger, A. S., Tuttle, K. R., & Quaggin, S. E. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.18641120 · Cited by 29
Self-citationLim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P. (2025) · Diabetologia · doi:10.1007/s00125-025-06439-x · Cited by 27
“…diabetes, discontinuation rates among those receiving active treat-ment have been less variable, ranging from 21% during a median follow-up time of 50 months in the DECLARE-TIMI 58 trial of dapagliflozin to 29% during a mean follow-up time of 43 months in the CANVAS trial of canagliflozin [14–18].”
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation
Schmidt, K., Schmidt, A., Groß, S., Just, A., Pfanne, A., Fuchs, M., Jordan, M., Mohr, E., Pich, A., Fiedler, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65410-9 · Cited by 33
“In support of this notion, a clinical trial investigating ertugliflozin reported no statistical superiority of the investigational drug in terms of treatment of cardiovascular disease in a diabetic context over placebo control 67 .”
BackgroundEmerging opportunities to target inflammation: myocardial infarction and type 2 diabetes
Kufazvinei, T. T. J., Chai, J., Boden, K. A., Channon, K. M., & Choudhury, R. P. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae142 · Cited by 34
“37 Subsequently, randomized clinical trials of other SGLT2 inhibitors including canagliflozin, 38,39 dapagliflozin 40 and ertugliflozin 41 have all been associated with a reduced risk of hospitalization for HF in people with T2D, demonstrating a consistent class-effect.”
BackgroundKumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Type 2 diabetes: summary of updated NICE guidance
Moran, G. M., Bakhai, C., Song, S. H., & Agwu, J. C. (2022) · BMJ · doi:10.1136/bmj.o775 · Cited by 32
SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad113 · Cited by 28
Sayour, A. A., Oláh, A., Ruppert, M., Barta, B. A., Merkely, B. P., & Radovits, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52331-w · Cited by 29
Fralick, M., Colacci, M., Thiruchelvam, D., Gomes, T., & Redelmeier, D. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14300 · Cited by 28
Ong, H. T., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Wee, C. F., Leong, S., Yip, A. S. Y., See, R. M., Ting, A. Z. H., Chia, A. Z. Q., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106159 · Cited by 30
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Jaiswal, V., Ang, S. P., Kumar, D., Deb, N., Jaiswal, A., Joshi, A., NASIR, Y. M., Bandyopadhyay, D., Michos, E. D., Benjamin, E. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101615 · Cited by 31
Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
Sayour, A. A., Ruppert, M., Oláh, A., Benke, K., Barta, B. A., Zsáry, E., Merkely, B. P., & Radovits, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189852 · Cited by 29
“VERTIS CV (ref: [6]) T2DM + established CVD ertugliflozin ~2200 CV death, nonfatal myocardial infarction, and nonfatal stroke 0.”
BackgroundGómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 27
Mao, L., Cai, D., Chi, B., Xiao, T., Zou, A., Wang, Y., Chen, Q., Gu, Q., Wang, Q., Ji, Y., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03495-3 · Cited by 29
“Existing studies suggest that in patients with T2DM and atherosclerotic cardiovascular disease, SGLT2 inhibitors reduce cardiovascular all-cause mortality and death from renal disorders, renal replacement therapy, or doubling of the serum creatinine level [37].”
BackgroundSeidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.303 · Cited by 25
Bhanushali, K. B., Asnani, H., Nair, A. V., Ganatra, S., & Dani, S. S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102664 · Cited by 28
Liang, I.-C., Chang, H.-H., Lai, Y.-J., Chan, C.-M., Sung, C.-H., Pu, C., Chang, D., Ho, C.-C., & Hung, C. (2025) · Medicina · doi:10.3390/medicina61020202 · Cited by 28
The year in cardiovascular medicine 2020: epidemiology and prevention
Estruch, R., Ruilope, L. M., & Cosentino, F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1062 · Cited by 27
Self-citationChan, Y., Chen, S., Chao, T., Kao, Y., Huang, C., & Chu, P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14446 · Cited by 26
“Chronic kidney disease 758 (17) 727 (20) 465 (20) 226 (23) 90 (21) <.”
Schechter, M., Cohen, C. M., Rozenberg, A., Yanuv, I., Chodick, G., Karasik, A., Kosiborod, M., & Mosenzon, O. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01362-y · Cited by 26
“Several CVOTs (EMPA-REG OUTCOME [1, 2], CANVAS program [4], DECLARE-TIMI 58 [6] and VERTIS CV [3]) tested the CV safety and efficacy of SGLT2i in patients with T2D and increased CV risk.”
BackgroundMethodSun, J., Liu, H., Zhang, Y., Fang, Z.-Y., & Lv, P. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105342 · Cited by 25
Zou, H., Yang, G., Cai, Y., Chen, H., Zheng, X., & Hu, R. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001222 · Cited by 25
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
Aboolian, A., Urner, S., Roden, M., Jha, J. C., & Jandeleit-Dahm, K. A. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_576 · Cited by 28
Cherney, D. Z. I., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., Pong, A., Cannon, C. P., et al. (2022) · American Journal of Nephrology · doi:10.1159/000524889 · Cited by 29
Self-citationKorayem, G. B., Alshaya, O. A., Alghamdi, A. A., ALANAZI, S., Almutib, R. T., Alsaileek, M., Alrashidi, A., Aldosari, N., Sheraim, N. B., Yami, M. S. A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1031306 · Cited by 26
Chan, G. C., Ng, J. K., Chow, K. M., & Szeto, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110200 · Cited by 29
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 27
Brønden, A., Christensen, M., Glintborg, D., Snorgaard, O., Kofoed‐Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15157 · Cited by 36
Uneda, K., Kawai, Y., Yamada, T., Kinguchi, S., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-89620-7 · Cited by 28
mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
Saha, S., Fang, X., Green, C. D., & Das, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015078 · Cited by 26
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors
Katsimardou, A., Theofilis, P., Vordoni, A., Doumas, M. N., & Kalaitzidis, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212384 · Cited by 31
“It should be noted that other SGLT2 inhibitors have demonstrated cardiovascular and renal benefits, such as ertugliflozin [20,21].”
Yoo, T. T., Baek, I. H., Stoletniy, L. N., Hilliard, A. A., Sakr, A. E., & Doycheva, D. M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02777-7 · Cited by 32
“Conversely, the VERTIS CV trial 2020 demonstrated noninferiority of ertugliflozin among patients with Type 2 DM and ASCVD in major adverse cardiovascular events compared to placebo, however, did not show superiority in composite of death from cardiovascular causes or HHF [97].”
Duan, X.-Y., Liu, S.-Y., & Yin, D. (2021) · Medicine · doi:10.1097/md.0000000000026431 · Cited by 31
“Nowadays, 3new CVOTs [13–15] respectively assessing sotagliflozin([14,15]) and ertugliflozin([13]) in T2D patients are available.”
BackgroundAlkabbani, W., Pelletier, R., Beazely, M. A., Labib, Y., Quan, B., & Gamble, J. (2022) · Drug Safety · doi:10.1007/s40264-022-01166-3 · Cited by 24
Lin, Y., Mok, M., Harrison, J., Battistella, M., Farrell, A., Leung, M., & Cheung, C. (2022) · Transplantation Reviews · doi:10.1016/j.trre.2022.100729 · Cited by 26
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A. D., Gragnano, F., Cozzolino, D., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805103 · Cited by 26
Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 25
Ko, H. Y., Bea, S., Jeong, H. E., Park, S., Cho, Y. M., Kong, S. H., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.35797 · Cited by 28
Rosén, H. C., Mohammad, M. A., Jernberg, T., James, S. K., Oldgren, J., & Erlinge, D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101032 · Cited by 26
SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot
Sawicki, K. T., Ben‐Sahra, I., & McNally, E. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021949 · Cited by 25
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.